TY - JOUR T1 - Targeting the Coronavirus Nucleocapsid Protein through GSK-3 Inhibition JF - medRxiv DO - 10.1101/2021.02.17.21251933 SP - 2021.02.17.21251933 AU - Xiaolei Liu AU - Anurag Verma AU - Gustavo Garcia, Jr. AU - Holly Ramage AU - Rebecca L. Myers AU - Anastasia Lucas AU - Jacob J. Michaelson AU - William Coryell AU - Arvind Kumar AU - Alexander W. Charney AU - Marcelo G. Kazanietz AU - Daniel J Rader AU - Marylyn D Ritchie AU - Wade H. Berrettini AU - David C. Schultz AU - Sara Cherry AU - Robert Damoiseaux AU - Vaithilingaraja Arumugaswami AU - Peter S. Klein Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/21/2021.02.17.21251933.abstract N2 - The coronaviruses responsible for severe acute respiratory syndrome (SARS-CoV), COVID-19 (SARS-CoV-2), Middle East respiratory syndrome (MERS-CoV), and other coronavirus infections express a nucleocapsid protein (N) that is essential for viral replication, transcription, and virion assembly. Phosphorylation of N from SARS-CoV by glycogen synthase kinase 3 (GSK-3) is required for its function and inhibition of GSK-3 with lithium impairs N phosphorylation, viral transcription, and replication. Here we report that the SARS-CoV-2 N protein contains GSK-3 consensus sequences and that this motif is conserved in diverse coronaviruses, raising the possibility that SARS-CoV-2 may be sensitive to GSK-3 inhibitors including lithium. We conducted a retrospective analysis of lithium use in patients from three major health systems who were PCR tested for SARS-CoV-2. We found that patients taking lithium have a significantly reduced risk of COVID-19 (odds ratio = 0.51 [0.35 - 0.74], p = 0.005). We also show that the SARS-CoV-2 N protein is phosphorylated by GSK-3. Knockout of GSK3A and GSK3B demonstrates that GSK-3 is essential for N phosphorylation. Alternative GSK-3 inhibitors block N phosphorylation and impair replication in SARS-CoV-2 infected lung epithelial cells in a cell-type dependent manner. Targeting GSK-3 may therefore provide a new approach to treat COVID-19 and future coronavirus outbreaks.Significance COVID-19 is taking a major toll on personal health, healthcare systems, and the global economy. With three betacoronavirus epidemics in less than 20 years, there is an urgent need for therapies to combat new and existing coronavirus outbreaks. Our analysis of clinical data from over 300,000 patients in three major health systems demonstrates a 50% reduced risk of COVID-19 in patients taking lithium, a direct inhibitor of glycogen synthase kinase-3 (GSK-3). We further show that GSK-3 is essential for phosphorylation of the SARS-CoV-2 nucleocapsid protein and that GSK-3 inhibition blocks SARS-CoV-2 infection in human lung epithelial cells. These findings suggest an antiviral strategy for COVID-19 and new coronaviruses that may arise in the future.Competing Interest StatementThe authors declare no competing interests. MDR is on the Scientific Advisory Board for Goldfinch Bio and Cipherome.Funding StatementPSK is supported by grants from the National Institutes of Health (1R01HL141759 and 1R01GM115517). VA is supported by the UCLA DGSOM and Broad Stem Cell Research Center institutional award (OCRC #20-15), National Institute of Health (1R01EY032149), and the California Institute for Regenerative Medicine TRAN Award (TRAN1COVID19-11975). We thank the Dean’s Innovation Fund, Linda and Laddy Montague, BWF, NIAID (5R01AI140539, 1R01AI1502461, R01AI152362), NCATS, the Fast Grants Award from Mercatus, and the Bill and Melinda Gates Foundation for funding to SC. SC is an Investigator in the Pathogenesis of Infectious Diseases from the Burroghs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EHR analysis was performed with Institutional Review Board (IRB) approval from the University of Pennsylvania (IRB #844360) and the Mt. Sinai Medical Center (IRB #20-00338).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request from the authors. Electronic Health Record data are available upon request from qualified investigators subject to a data use agreement and IRB approval. ER -